Federal health officials cut the number of vaccines the Centers for Disease Control and Prevention routinely recommends for children from 17 to 11 following a directive from the White House. The decision, announced by HHS and implemented without the agency’s usual public advisory process, reclassifies six previously routine vaccines as targeted "shared decision-making" or high‑risk recommendations. The change was driven by a review led by HHS appointees and reflects an effort to align U.S. recommendations more closely with some peer nations, according to the administration. Public-health groups and parts of the medical community warned the move could lower vaccination uptake, while the HHS said insurance coverage for all 17 vaccines would continue. Industry groups including BIO quickly criticized the overhaul as unscientific, saying the abrupt change undermines public trust and may increase preventable disease risk. The dispute raises immediate implementation questions for state immunization rules and could affect pediatric vaccine markets and development priorities if uptake and payer behavior shift.